fda tirzepatide injection shortage resolved october 2 2024 Affirms Decision on Resolved, Sets Transition Period for Compounding FDA declares Mounjaro, Zepbound shortage

A clear to slightly yellow solution is normal

The SURMOUNT-OSA trial demonstrates that treatment of obesity with tirzepatide is an effective treatment for OSA, and its possible that combination therapy with tirzepatide plus continuous positive airway pressure (CPAP) is really the optimal treatment for OSA and obesity-related cardiometabolic risk. Based on the findings from the SURMOUNT-OSA trial, he believes tirzepatide could become the first medication approved for treatment of sleep apnea in patients with obesity

Patients should consume fluids regularly throughout the day Small Frequent Meals Eating some small meals throughout the day can prevent digestive overload

But "more weight loss" doesn't automatically mean "better for you." The right medication depends on your medical history, your insurance situation, your tolerance for side effects, and frankly which one you can actually access and afford in 2026

[1] [4] The pharmacokinetic profile of tirzepatide supports safe discontinuation without tapering

Tirzepatide currently offers the best combination of robust data, proven efficacy, and established safety profile among the multi-agonist weight loss peptides